Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib in HeFH and/or ASCVD with inadequate lipid control
NCT05142722Phase 3Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Dec 2021
- Primary completion
- Sep 2024
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD) comparing Placebo with Obicetrapib 10mg (2 arms). Primary endpoint: Low-Density Lipoprotein Cholesterol at 84 days. Started Dec 2021; status: completed.
02
Drugs
obicetrapib
03
Conditions
hypercholesterolemiaatherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT05142722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142722.